- Home
- LFT vs PRLD Comparison
LFT vs PRLD Comparison
Compare LFT & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFT | PRLD |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.1M | 69.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | LFT | PRLD |
|---|---|---|
| Price | $1.37 | $3.14 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $4.67 |
| AVG Volume (30 Days) | 134.0K | ★ 318.9K |
| Earning Date | 01-01-0001 | 06-17-2026 |
| Dividend Yield | ★ 11.68% | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,140,000.00 |
| Revenue This Year | $124.75 | $320.10 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | $13.49 | ★ N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $1.26 | $0.61 |
| 52 Week High | $2.84 | $4.19 |
Technical Indicators
Market Signals| Indicator | LFT | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 51.79 | 57.17 |
| Support Level | $1.26 | $0.99 |
| Resistance Level | $1.41 | $4.19 |
| Average True Range (ATR) | 0.04 | 0.36 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 58.33 | 45.21 |
Price Performance
Historical ComparisonAbout LFT Lument Finance Trust Inc.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.